News + Resources
Pro-Innovation Mergers & Acquisitions: Maintaining America’s Leadership in Biopharmaceutical Breakthroughs
Thousands of U.S. life sciences companies race every day to find better treatments and cures for a wide range of conditions and diseases. Within this diverse and dynamic life sciences ecosystem – made up of early-stage companies, large-scale entities, research universities and other researchers across the public and private sectors – mergers and acquisitions (M&A) fuel America’s global leadership in biopharmaceutical breakthroughs.
The Pro-Competition Policies Driving Life Science Innovation
America has a long history of enacting sound, bipartisan policies that have created powerful incentives for life sciences innovators to invest in the costly, extensive research and development (R&D) process behind groundbreaking treatments and cures. These pro-innovation policies have been carefully balanced by market protections that promote access to a wide range of treatment options for patients.